These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 19146764)

  • 1. Management of severe OHSS using GnRH antagonist and blastocyst cryopreservation in PCOS patients treated with long protocol.
    Lainas TG; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas GT; Iliadis GS; Kolibianakis EM
    Reprod Biomed Online; 2009 Jan; 18(1):15-20. PubMed ID: 19146764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of severe early ovarian hyperstimulation syndrome by re-initiation of GnRH antagonist.
    Lainas TG; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas GT; Kolibianakis EM
    Reprod Biomed Online; 2007 Oct; 15(4):408-12. PubMed ID: 17908403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS.
    Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas TG; Tarlatzis BC
    Hum Reprod; 2013 Jul; 28(7):1929-42. PubMed ID: 23624582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated with Corifollitropin alfa or rFSH in a GnRH Antagonist Protocol.
    Griesinger G; Verweij PJ; Gates D; Devroey P; Gordon K; Stegmann BJ; Tarlatzis BC
    PLoS One; 2016; 11(3):e0149615. PubMed ID: 26950065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum vascular endothelial growth factor levels following luteal gonadotrophin-releasing hormone antagonist administration in women with severe early ovarian hyperstimulation syndrome.
    Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas TG; Tarlatzis BC
    BJOG; 2014 Jun; 121(7):848-55. PubMed ID: 24621101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe ovarian hyperstimulation syndrome after combined GnRH-agonist and low-dose human chorionic gonadotropin trigger in a patient with a single kidney.
    Pereira N; Lekovich JP; Kligman I; Rosenwaks Z
    Gynecol Endocrinol; 2017 Aug; 33(8):593-597. PubMed ID: 28440686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Live births after management of severe OHSS by GnRH antagonist administration in the luteal phase.
    Lainas TG; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas GT; Alexopoulou E; Kolibianakis EM
    Reprod Biomed Online; 2009 Dec; 19(6):789-95. PubMed ID: 20031018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outpatient management of severe early OHSS by administration of GnRH antagonist in the luteal phase: an observational cohort study.
    Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Tarlatzi TB; Tarlatzis BC; Lainas TG
    Reprod Biol Endocrinol; 2012 Aug; 10():69. PubMed ID: 22938051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
    Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
    Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.
    Prapas Y; Ravanos K; Petousis S; Panagiotidis Y; Papatheodorou A; Margioula-Siarkou C; Iuliano A; Gullo G; Prapas N
    J Assist Reprod Genet; 2017 Nov; 34(11):1537-1545. PubMed ID: 28776117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GnRH antagonist rescue in high responders at risk for OHSS results in excellent assisted reproduction outcomes.
    Hill MJ; Chason RJ; Payson MD; Segars JH; Csokmay JM
    Reprod Biomed Online; 2012 Sep; 25(3):284-91. PubMed ID: 22796230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triggering ovulation with gonadotropin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol levels.
    Manzanares MA; Gómez-Palomares JL; Ricciarelli E; Hernández ER
    Fertil Steril; 2010 Mar; 93(4):1215-9. PubMed ID: 19200978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
    Babayof R; Margalioth EJ; Huleihel M; Amash A; Zylber-Haran E; Gal M; Brooks B; Mimoni T; Eldar-Geva T
    Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.
    Seyhan A; Ata B; Polat M; Son WY; Yarali H; Dahan MH
    Hum Reprod; 2013 Sep; 28(9):2522-8. PubMed ID: 23633553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a "freeze-all" strategy: a prospective multicentric study.
    Griesinger G; Schultz L; Bauer T; Broessner A; Frambach T; Kissler S
    Fertil Steril; 2011 May; 95(6):2029-33, 2033.e1. PubMed ID: 21371705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double GnRH-antagonist dose before HCG administration may prevent OHSS in oocyte-donor cycles: a pilot study.
    Prapas Y; Panagiotidis I; Kalogiannidis I; Gjata E; Papatheodorou A; Prapa S; Kasapi L; Goudakou M; Prapas N
    Reprod Biomed Online; 2010 Aug; 21(2):159-65. PubMed ID: 20627811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prevention of ovarian hyperstimulation syndrome.
    Corbett S; Shmorgun D; Claman P; ;
    J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A simplified universal approach to COH protocol for IVF: ultrashort flare GnRH-agonist/GnRH-antagonist protocol with tailored mode and timing of final follicular maturation.
    Orvieto R
    J Ovarian Res; 2015 Nov; 8():69. PubMed ID: 26536862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuation of GnRH agonist administration for 1 week, after hCG injection, prevents ovarian hyperstimulation syndrome following elective cryopreservation of all pronucleate embryos.
    Endo T; Honnma H; Hayashi T; Chida M; Yamazaki K; Kitajima Y; Azumaguchi A; Kamiya H; Kudo R
    Hum Reprod; 2002 Oct; 17(10):2548-51. PubMed ID: 12351526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.